Metabotropic glutamate receptors and drug ... - Wiley Online Library

Advanced Review

Metabotropic glutamate receptors and drug addiction Richard M. Cleva and M. Foster Olive∗

Historically, brain catecholamine systems have been the primary focus of studies examining the neural substrates of drug addiction. In the past two decades, however, a wealth of evidence has accumulated indicating a pivotal role for glutamatergic neurotransmission in mediating addictive behaviors as well as longterm neuroplasticity associated with chronic drug use. As a result, there has been increased interest in developing glutamate-based therapies for the treatment of addictive disorders. Metabotropic glutamate (mGlu) receptors are classified into subcategories designated as Group I (mGlu1 and mGlu5), Group II (mGlu2 and mGlu3), and Group III (mGlu4, mGlu6, mGlu7, and mGlu8) and have received a great deal of attention due to their mediation of slower modulatory excitatory neurotransmission. Pharmacological ligands targeting these receptors have demonstrated reduced incidences of excitotoxicity or severe adverse side effects as compared to those targeting ionotropic glutamate (iGlu) receptors. Behavioral genetic and pharmacological studies have explored the role of individual mGlu receptor subtypes in regulating various addiction-related behaviors, and several mGlu receptor ligands have been the subject of clinical testing for other medical conditions. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. How to cite this article:

WIREs Membr Transp Signal 2012, 1:281–295. doi: 10.1002/wmts.18

INTRODUCTION

L

-Glutamate is the most abundant excitatory neurotransmitter in the central nervous system (CNS) and governs many processes in the brain including fast and slow excitatory neurotransmission, control of basal neuronal activity, and synaptic plasticity. Historically, studies examining the neural basis of drug addiction have focused primarily on brain catecholaminergic neurotransmission. However, a tremendous amount of preclinical and clinical evidence has recently accumulated suggesting that glutamate plays a pivotal role in drug self-administration, rewardrelated processes, drug-induced conditioned associations, and relapse.1–3 Glutamatergic signaling in the brain is primarily mediated by both ionotropic glutamate (iGlu) and metabotropic glutamate (mGlu) receptors. While pharmacological manipulations of iGlu receptors have been shown to decrease numerous addictionrelated behaviors, iGlu receptor ligands produce ∗

Correspondence to: [email protected] Department of Psychology, Arizona State University, Tempe, AZ, USA

Volume 1, May/June 2012

many adverse side effects, including excitotoxicity, psychosis-like symptoms and dissociative states, and alterations in general CNS excitability. mGlu receptors, on the other hand, exert more subtle modulatory influences on excitatory neurotransmission. Many animal and human studies conducted to date have shown that mGlu receptor ligands have potential for the treatment of numerous disorders of the CNS, including chronic pain, schizophrenia, depression, anxiety, epilepsy, Parkinson’s disease and other neurodegenerative diseases,4–7 and, as will be described in this review, drug addiction. To date, eight different mGlu receptor subtypes have been cloned and characterized, and each appears to have a diverse neuroanatomical distribution as well as unique pharmacological and intracellular signaling properties.8,9 mGlu receptors are typically subcategorized into Group I receptors (mGlu1 and mGlu5), which are coupled to various classes of G-proteins such as Gq/11 . On activation, these receptors stimulate the release of calcium from intracellular stores. In contrast, Group II (mGlu2 and mGlu3) and Group III (mGlu4, mGlu6, mGlu7, and mGlu8) receptors are coupled to Gi/o protein signaling mechanisms and,

© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

281

wires.wiley.com/mts

Advanced Review

upon activation, reduce the formation of intracellular cyclic adenosine monophosphate via inhibition of adenylyl cyclase activity. The purpose of the present review is to summarize studies conducted to date that have provided strong evidence that individual mGlu receptor subtypes regulate various addiction-related behaviors. We will also review the safety, tolerability, efficacy, and side effects profile of several mGlu receptor ligands that are currently in clinical trials for other medical conditions. These clinical studies are critical for establishing the feasibility of utilizing such compounds as pharmacological aids in the treatment of drug addiction.

GROUP I mGlu RECEPTORS AND ADDICTION mGlu1 and mGlu5 receptors have an almost complementary pattern of anatomical distribution in the brain.10 High levels of mGlu5 receptors are found in forebrain regions such as the cerebral cortex, dorsal and ventral striatum [including the nucleus accumbens (NAc)], olfactory bulb and tubercle, lateral septum, and hippocampus.11,12 In contrast, expression levels of mGlu1 receptors in these regions are relatively weak, except for the hippocampus, where this receptor is highly expressed primarily in the CA3 region and dentate gyrus. Regions containing high levels of expression of mGlu1 receptors that have low levels of mGlu5 expression include the cerebellum, thalamus, hypothalamus, and pallidum.13 Electron microscopy studies have shown that Group I mGlu receptors are primarily localized on postsynaptic elements and are rarely found on presynaptic terminals.12

mGlu5 Receptors Although the mGlu5 receptor was first cloned and characterized in the early 1990s,14 its role in drug addiction did not become evident until 2001 in a highly influential study published by Chiamulera et al.15 These investigators demonstrated that mice carrying a null mutation for the gene encoding the mGlu5 receptor failed to demonstrate hyperlocomotion in response to acute administration of various doses of cocaine [10, 20, or 40 mg/kg intraperitoneally (i.p.)] and also failed to acquire intravenous self-administration of cocaine at various doses, while wild-type mice demonstrated typical patterns of selfadministration. Chiamulera et al. also showed that pharmacological antagonism of mGlu5 receptors with 2-methyl-6-(phenylethynyl)-pyridine (MPEP) dose dependently reduced intravenous cocaine selfadministration. This pivotal study provided the first 282

evidence that either genetic or pharmacological inhibition of mGlu5 receptors could reduce the locomotor stimulant and reinforcing effects of cocaine. Although the findings of Chiamulera et al. were highly influential in instigating the study of mGlu5 receptors in addiction research, it should be noted that several subsequent studies have failed to completely replicate these results. For example, Bird et al.16 demonstrated that acute administration of cocaine (20 mg/kg i.p.) increased locomotor activity in both wild-type and mGlu5-deficient mice, although the effects in mGlu5-deficient mice were somewhat delayed in comparison to those observed in wildtype mice. In addition, using cell type-specific RNA interference to selectively reduce mGlu5 expression on dopamine D1 receptor-expressing neurons in the dorsal striatum, Novak et al.17 showed that patterns of cocaine self-administration were similar in wildtype and mGlu5 knockdown mice. These findings suggest that the dorsal striatum does not mediate the effects of mGlu5 receptor inhibition on cocaine reinforcement. As will be discussed below, there is evidence to suggest that mGlu5 receptors in regions of the ventral striatum, particularly the NAc, are in fact implicated in mediating drug reinforcement and relapse-like behaviors. Despite these two studies that seemingly contradict the original findings of Chiamulera et al., a host of pharmacological studies have subsequently shown that blockade of mGlu5 receptors attenuates the acquisition and/or expression of the conditioned rewarding effects of cocaine,18 nicotine,19 amphetamine,20 morphine,21–23 and alcohol,24 as measured by the conditioned place preference (CPP) paradigm. On the other hand, recent studies have reported contradictory findings that MPEP actually potentiates the acquisition of CPP for heroin,25,26 ketamine,25,26 cocaine,26 nicotine,26 and morphine27 and reinstates for heroin- and ketamine-induced CPP.25 In addition, these same investigators demonstrated that intravenous MPEP induces CPP on its own,28 although relatively high doses (3 and 10 mg/kg intravenously) were needed to observe such effects, and MPEP is known to exert nonselective effects on other glutamate receptors at high concentrations.29 While these phenomena have not yet been demonstrated for other more selective mGlu5 antagonists, these findings suggest the possibility that the ability of such compounds to reduce intravenous drug self-administration (see below) may be due to a pharmacologically induced increase in the rewarding effects of these abused substances. In animals actively self-administering various drugs of abuse (intravenously) or alcohol (orally),



WIREs Membrane Transport and Signaling

pharmacological blockade or genetic inactivation of mGlu5 receptors reduces self-administration of cocaine,15,30–37 nicotine,33,38–41 heroin,42 ketamine,42 methamphetamine,43 and alcohol24,44–53 and can also reduce breakpoints for reinforcement for various drugs of abuse in a progressive ratio paradigm.43,54,55 mGlu5 receptor antagonism can also interfere with the interoceptive effects of some drugs of abuse such as alcohol,56 nicotine,57 and cocaine,34 which may contribute to the ability of mGlu5 receptor antagonists to reduce self-administration of these drugs. In studies of animals self-administering natural reinforcers such as food, mGlu5 receptors appear to be required for the acquisition of the incentive properties of reinforcer-associated conditioned stimuli58 as well as operant sensation seeking,59 which may also contribute to the ability of mGlu5 antagonists to attenuate drug self-administration. Interestingly, it has been demonstrated that in rats self-administering heroin, intravenous MPEP will substitute for heroin and maintain lever pressing,28 albeit to a limited degree. Additional studies examining this phenomenon with more selective mGlu5 antagonists are needed to confirm these observations. One of the most problematic obstacles to the successful treatment of drug addiction is the phenomenon of relapse. Pharmacological blockade of mGlu5 receptors has been shown to attenuate the reinstatement of drug-seeking behavior induced by drug priming, stress, or drug-associated cues,33,34,36,43,44,52,60–66 which are established animal models of relapse. In addition, mGlu5 receptor antagonism also reduces the surge in alcohol intake when it is reintroduced following a period of forced abstinence.44,49 Together, these studies suggest that mGlu5 antagonists not only reduce ongoing drug use but may aid in the prevention of relapse. Although all of the aforementioned studies have utilized systemic administration of mGlu5 receptor antagonists or embryonic genetic deletion of the mGlu5 receptor gene, only a handful of studies to date have examined the precise neuroanatomical loci where drug reward, reinforcement, or reinstatement of drug-seeking behavior is mediated by these receptors. Blockade of mGlu5 receptors in the NAc has been shown to attenuate both intravenous and oral alcohol reinforcement,67–69 as well as the interoceptive effects of alcohol.70 Similarly, blockade of mGlu5 receptors in the NAc has also been shown to attenuate cocaine- or cue-primed reinstatement of cocaine-seeking behavior.60,71 Finally, Novak et al. showed that knockdown of mGlu5 expression on dopamine D1 receptor-expressing neurons in the dorsal striatum did not alter patterns of cocaine Volume 1, May/June 2012

Metabotropic glutamate receptors and addiction

self-administration but attenuated cue-induced reinstatement of cocaine seeking.17 Thus, it appears that mGlu5 receptors in dopaminoceptive regions of the forebrain differentially mediate cocaine reinforcement versus the incentive salience of drug-associated cues. As with all studies that document a pharmacological suppression of drug reward, reinforcement, or drug-seeking behavior, it is important to consider the possibility that any observed effects may be due to nonspecific inhibitory effects of the test compounds on locomotor activity. This is especially important in light of the fact that fenobam, an mGlu5 antagonist currently in clinical trials for the treatment of Fragile X syndrome, has been reported to produce mild sedation.72 While many of the aforementioned studies have demonstrated that mGlu5 antagonists such as MPEP and 3-((2-methyl-4-thiazolyl)ethynyl)pyridine (MTEP) do not alter spontaneous locomotor activity, some have reported that these ligands, particularly at higher doses, produce moderate impairments of locomotor activity.33,54,73 This underscores the importance of incorporating appropriate locomotor control experiments into studies on the ability of mGlu5 antagonists (or any mGlu receptor ligand) on addiction-related behaviors to monitor for the possibility of confounding motor effects (Box 1).

mGlu1 Receptors Compared with the extensive literature reviewed above on the role of mGlu5 receptors in mediating drug reward, reinforcement, and relapse, relatively few studies have been published on the specific role of mGlu1 receptors. Several investigators have found a lack of effect of mGlu1 receptor antagonism on voluntary alcohol self-administration in rodents.48,49 However, Lominac et al.24 found an inhibitory effect of an mGlu1 receptor antagonist on alcohol self-administration in mice. A more recent study showed that the potent mGlu1 receptor antagonist JNJ16259685 reduces alcohol self-administration as well as breakpoints for alcohol reinforcement in a progressive ratio paradigm, but nonspecific impairments in motor activity were also induced by this compound.54,84 Thus, to date, the role of mGlu1 receptors in regulating alcohol consumption are still not clearly defined. Further studies are needed to examine the effects of mGlu1 receptor antagonists that are devoid of motor side effects on self-administration of alcohol and other drugs of abuse. With regard to relapse-like behaviors, it has been demonstrated that the selective mGlu1 receptor antagonist (3-ethyl-2-methyl-quinolin-6-yl)(4-methoxy-cyclohexyl)-methanone (EMQMCM)


283

wires.wiley.com/mts

Advanced Review

BOX 1 POSITIVE ALLOSTERIC MODULATION OF MGLU5 RECEPTORS—A NOVEL MECHANISM TO ENHANCE EXTINCTION LEARNING AND COGNITIVE DEFICITS ASSOCIATED WITH DRUG ADDICTION? While mGlu5 receptor blockade attenuates the rewarding and reinforcing effects of multiple drugs of abuse, there is also evidence that mGlu5 receptor blockade also impairs certain forms of learning and memory.74,75 This is likely due to the fact that postsynaptic mGlu5 receptor function is positively coupled to postsynaptic N-methyl-D-aspartate (NMDA) receptor function, which are critical for the induction of synaptic plasticity associated with learning and memory. Recently, increased attention has been given to the development of pharmacological compounds that enhance, rather than inhibit, mGlu5 receptor function. These compounds are collectively known as mGlu5 positive allosteric modulators (PAMs), as they bind to an allosteric site that is distinct from the orthosteric glutamate-binding site of the receptor. mGlu5 receptor PAMs are devoid of any agonistic activity on their own but potentiate receptor response to endogenously released glutamate. Commonly used systemically active mGlu5 receptor PAMs include 3-cyano-N-(1,3-diphenyl -1H-pyrazol-5-yl) benzamide (CDPPB)76 and [S(4-fluoro-phenyl)-[3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl]-methanone] (ADX 47273).77,78 Drug-associated memories evoked by exposure to contexts or distinct environmental stimuli that have been repeatedly paired with drug use often result in drug craving and relapse. Therefore, extinction of the motivational salience of drug-associated cues and contexts may lead to reduced incidences of relapse,79 and recent evidence suggests that mGlu5 receptors play an important role in extinction learning processes. For example, mGlu5 receptor-deficient mice fail to extinguish conditioned fear behaviors.80 In contrast, the mGlu5 PAM CDPPB facilitates the extinction of the conditioned rewarding effects of cocaine81 as well as cocaine-seeking behavior following intravenous self-administration.82 In addition, mGlu5 PAMs appear to have some cognition-enhancing properties, as CDPPB can reverse cognitive deficits produced by extended access to methamphetamine.83 Since cognitive deficits are frequently observed in chronic drug

284

users, mGlu5 PAMs may represent a novel approach to facilitating the extinction of the motivational salience of drug-associated stimuli, as well as reversing some of the cognitive deficits caused by chronic drug use.

attenuates the reinstatement of nicotine-seeking behavior elicited by nicotine priming and nicotineassociated cues.85 Antagonism of mGlu1 receptors in the dorsal hippocampus has been reported to attenuate the reinstatement of cocaine-seeking behavior evoked by cocaine-associated contextual cues,86 consistent with a well-defined role of the hippocampus in contextual memory. Thus, mGlu1 receptors may play a role in the processing of drug-associated contextual cues. Studies examining the effects of pharmacological manipulation of mGlu1 receptors in other brain regions known to be involved in addiction (i.e., amygdala, ventral tegmental area, prefrontal cortex, etc.) on drug self-administration and relapse are needed to provide a more comprehensive understanding of the neural circuitry in which these receptors regulate various aspects of drug addiction.

GROUP II mGlu RECEPTORS AND ADDICTION mGlu2 and mGlu3 Receptors mGlu2 and mGlu3 receptors are predominantly expressed as heterodimers on presynaptic membranes of glutamatergic terminals and negatively regulate the release of glutamate, although there is also evidence that these receptors are also located in peripheral regions of the synapse.87–89 mGlu2 and mGlu3 receptors are found in moderate to high abundance in the olfactory bulb, cerebral cortex, septal region, hippocampus, dorsal and ventral striatum, amygdala, and cerebellum.89–92 Since these receptors are predominantly found as heterodimers, the receptor complexes are frequently referred to as mGlu2/3 receptors, although homodimers of each receptor subtype have been identified. One of the first demonstrations that mGlu2/3 agonists might possess therapeutic efficacy in the treatment of drug addiction was published in 1997, when it was shown that the mGlu2/3 agonist LY354740 suppressed somatic signs of nicotine withdrawal in rats.93 Since this study, there have been numerous reports that mGlu2/3 agonists reduce active drug self-administration and drug-seeking behavior. For example, mGlu2/3 agonists such as LY379268 and LY404039 have been shown to suppress self-administration of cocaine,37,94–96 nicotine,40




and ethanol,52,97,98 as well as cue-, stress-, and drug priming-induced reinstatement of drug seeking.52,94,96,98,99 mGlu2/3 agonists have also been shown to attenuate the phenomenon of ‘incubation’ of cocaine craving,100 which is characterized by a progressive increase in the magnitude of cue-induced reinstatement over time following extinction.101,102 Some of the aforementioned effects of mGlu2/3 agonists must be interpreted with caution, however, since higher doses (3–5 mg/kg i.p.) of mGlu2/3 agonists such as LY379268 have been shown to decrease spontaneous locomotor activity98 as well as selfadministration of natural reinforcers such as food95 and sweetened solutions.97 In light of these nonspecific effects of mGlu2/3 agonists, recent studies have shown that such effects are lacking following administration of mGlu2 PAMs, such as 3 -(((2-cyclopentyl6,7-dimethyl-1-oxo-2,3-dihydro-1H-inden-5-yl)oxy) methyl)biphenyl-4-carboxylic acid (BINA)103 and 3-chloro-3 -((2-cyclopentyl-3-oxo-2,3-dihydrobenzo [d]isothiozal-6-yloxy)methyl)biphenyl-4-carboxylic acid,104 while maintaining their ability to suppress drug self-administration. Positive allosteric modulation of mGlu2 (and possibly mGlu3) receptors may therefore be a novel pharmacological approach, to reduce drug self-administration without motoric side effects. It should also be mentioned that tolerance to the motor impairing effects of classical mGlu2/3 agonists such as LY379268 has been reported,105 suggesting that unwanted motoric side effects of such ligands may dissipate following repeated administration. Studies employing intracerebral microinjection techniques have revealed some of the neural circuitries involved in the ability of mGlu2/3 agonists to reduce drug reinforcement or reinstatement. For example, infusion of LY379268 into the ventral tegmental area attenuates nicotine self-administration106 as well as contextual cue-induced reinstatement of heroin seeking.107 Infusions of LY379268 into the NAc shell attenuate nicotine but not food reinforcement,106 while infusions of LY379268 into the NAc attenuate both cocaine and food-primed reinstatement of cocaine- and food-seeking, respectively.95 Infusion of this ligand into the NAc core or shell also reduces context-induced reinstatement of heroinseeking without affecting sucrose seeking.108 Finally, it was recently demonstrated that infusions of LY379268 into the central nucleus of the amygdala attenuates the ‘incubation’ of cocaine craving.100 Thus, structures of the mesolimbic reward system and extended amygdala appear to be regions where mGlu2/3 receptors mediate addiction-related behaviors. Volume 1, May/June 2012


GROUP III mGlu RECEPTORS AND ADDICTION The existing literature on the role of Group III mGlu receptors in mediating drug addiction is somewhat minute, largely because of the general lack of availability of pharmacological ligands that are selective for individual subtypes of Group III mGlu receptors. The expression patterns of Group III receptors in the brain are also more limited than those of Group I and II mGlu receptors. mGlu6 receptor expression is confined to the retina,109 thus making it an unattractive target for potential anti-addiction pharmacotherapies. mGlu4 receptors have a limited distribution in the CNS, being expressed predominantly on presynaptic terminals at high levels in the cerebellum, basal ganglia, thalamus, and hippocampus.110 In contrast, mGlu7 receptors are expressed much more widely throughout the CNS including the cerebral cortex, striatum, hippocampus, hypothalamus, and cerebellum, where they are predominantly localized to presynaptic terminals.111 Finally, mGlu8 receptors have a restricted distribution in the brain, primarily being confined to olfactory bulb, piriform cortex, hippocampus, thalamus, and pons.112

mGlu4 Receptors To our knowledge, only one study has been conducted that specifically examined the role of mGlu4 receptors in addiction-related behaviors. Blednov et al.113 demonstrated that mice lacking mGlu4 receptors showed normal levels of ethanol consumption but lacked a locomotor stimulant effect of low doses of alcohol. These findings indicate that behavioral responses to acute administration of alcohol do not necessarily predict alcohol consumption patterns in genetically altered mice.

mGlu7 Receptors Similar to findings from studies on mGlu2/3 receptors, stimulation of presynaptic mGlu7 receptors with the selective mGlu7 agonist AMN082 results in suppression of cocaine self-administration, and similar effects are observed when this ligand is infused into the NAc or ventral pallidum.114 AMN082 has also been reported to attenuate cocaine-primed reinstatement of cocaine-seeking behavior.115 Doses of AMN082 that are similar to those used in these studies have also been found to suppress alcohol selfadministration,116 but nonselective inhibitory effects of this compound on sucrose self-administration and locomotor activity were also found. Thus, the development of mGlu7-selective ligands devoid of these


285

wires.wiley.com/mts

Advanced Review

nonselective effects is necessary in order to fully establish a role for these receptors in drug reward and reinforcement. Despite these limitations, gene mapping techniques in mice have revealed that the gene encoding the mGlu7 receptor is a cis-regulated gene that predisposes the organism toward higher levels of alcohol consumption,117 suggesting that the mGlu7 receptor may indeed be a potential target for suppressing high levels of alcohol intake.

mGlu8 Receptors Backstrom and Hyytia98 demonstrated that administration of the mGlu8 agonist (S)-3,4-dichlorophenyl glycine ((S)-3,4-DCPG) suppressed alcohol selfadministration as well as cue-induced reinstatement of alcohol-seeking behavior. However, doses of (S)-3, 4-DCPG that were effective at reducing alcohol consumption and reinstatement were also accompanied by reductions in locomotor activity. Thus, as with mGlu2/3 and mGlu7 receptors, there is need for the development of improved mGlu8 ligands that are devoid of nonspecific motoric effects (Table 1).

EFFECTS OF ADDICTIVE DRUGS ON mGlu RECEPTOR EXPRESSION AND FUNCTION The preceding sections have summarized findings on the effects of mGlu receptor ligands in rodent models of addictive behaviors, such as conditioned drug reward, drug self-administration, and reinstatement. However, since addictive drugs exert long-lasting

effects on the brain such as changes in synaptic transmission, gene expression, protein localization and function, neuronal morphology, and the integrity of neural circuits, it is important to consider the effects of long-term exposure to drugs of abuse on the expression and/or function of mGlu receptors, particularly if these receptors are to be targeted by novel pharmacotherapeutics for the treatment of addictive disorders. Studies using quantitative in situ hybridization techniques have shown that repeated exposure to amphetamine produces lasting reductions in the expression of mGlu5 mRNA in the dorsal striatum and NAc, while the expression of mGlu8 mRNA is increased in these regions118 and mGlu1 mRNA levels are only transiently affected.119 In contrast, increases in the expression of mGlu5 mRNA in these regions have been observed following repeated exposure to cocaine.120 Repeated cocaine exposure also disrupts mGlu1- and mGlu2/3-mediated signaling in the NAc.121,122 Chronic alcohol consumption has been shown to reduce mGlu1, mGlu3, mGlu5, and mGlu7 mRNA levels in various subregions of the hippocampus while leaving the expression of mGlu2, mGlu4, and mGlu8 unchanged.123 While examinations of changes in mRNA levels are general indirect measures of changes in receptor levels, a small number of recent studies have examined drug-induced changes in overall protein levels as well as cellular distribution and trafficking of mGlu receptors. Chronic ethanol consumption in alcoholpreferring P rats has been shown to increase the expression of mGlu1 and mGlu5 levels in the NAc

TABLE 1 Summary of Primary Findings on Effects of mGlu Ligands in Rodent Models of Addiction Receptor

Pharmacological Action

Behavioral Effect

Drugs

mGlu1

Antagonism

Reduced reinstatement of drug seeking

Cocaine, nicotine

mGlu5

Antagonism or negative allosteric modulation

Reduced conditioned reward (CPP)

Alcohol, amphetamine, cocaine, morphine, nicotine

Reduced self-administration

Alcohol, cocaine, ketamine, methamphetamine, nicotine

Positive allosteric modulation mGlu2/3

mGlu7 mGlu8

286

Agonism or positive allosteric modulation Agonism Agonism


Alcohol, cocaine, methamphetamine, nicotine

Reduced extinction responding

Cocaine

Reversal of drug-induced cognitive deficit

Methamphetamine

Reduced self-administration

Alcohol, cocaine, nicotine


Alcohol, cocaine, heroin, nicotine

Reduced ‘incubation’ of drug craving

Cocaine

Reduced drug self-administration

Alcohol, cocaine


Cocaine

Reduced drug self-administration

Alcohol


Alcohol




core and central nucleus of the amygdala,124 while repeated cocaine exposure results in a decrease in the expression of mGlu2/3 receptors in the NAc core.125 Using electron microscopy methods, Mitrano et al.126 found minimal effects of repeated cocaine exposure on the percentage of membrane-bound mGlu1 or mGlu5 receptors in the NAc core and shell subregions. However, investigators utilizing subcellular fractionation techniques have shown that repeated cocaine increases the levels of mGlu2/3 and mGlu5 receptors in synaptosomal membrane fractions from the NAc core.125 Together, these drug-induced alterations in mGlu mRNA and protein levels as well as the subcellular redistribution of mGlu receptors may underlie some of the functional changes in glutamatergic transmission and synaptic plasticity that occur as a result of chronic drug use.127,128 It therefore follows that such changes may influence the ability of mGlu ligands to alter addiction-related behaviors. This point is exemplified in a study by Sidhpura et al.,52 who demonstrated that the mGlu2/3 agonist LY379268 suppressed foot-shock stress-induced reinstatement of alcohol-seeking behavior in rats both before and after the induction of physical dependence, whereas the mGlu5 antagonist MTEP appeared to be less effective in reducing foot-shock-induced reinstatement following the induction of dependence.

CURRENT STATUS OF mGlu RECEPTOR LIGANDS IN HUMAN CLINICAL TRIALS Several mGlu5 (but not mGlu1) receptor antagonists [or negative allosteric modulators (NAMs), which dampen the activity of the receptor without rendering it completely inactive] have now entered Phase I and II clinical trials for the treatment of other medical conditions, including Fragile X syndrome, gastroesophageal reflux disease (GERD), anxiety, depression, and l-dopa-induced dyskinesia in Parkinson’s disease.5–7,129,130 Since the number of published pilot clinical studies is relatively small, the data thus far on the clinical efficacy, safety, tolerability, and side effect profiles of these compounds are relatively limited in detail. Approximately a decade prior to the isolation and characterization of the mGlu5 receptor in 1992, several clinical studies were conducted with a compound called fenobam (N-(3-chlorophenyl-N -(4,5)dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea) for the treatment of anxiety.131–134 At the time of these studies, fenobam had an unknown mechanism of Volume 1, May/June 2012


action and was referred to as a ‘nonbenzodiazepine anxiolytic’. In 2005, fenobam was recharacterized and found to be an mGlu5 receptor antagonist with greater selectivity for the receptor than MPEP.135,136 The results of these early clinical studies demonstrated significant anxiolytic effects of fenobam that were equivalent to those produced by diazepam, but adverse side effects such as nausea, dizziness, insomnia, blurred vision, depersonalization, and perceptual alterations were reported in approximately 25–40% of patients. Many patients who experienced these side effects discontinued the study. These adverse side effects occurred primarily in patients taking higher doses of fenobam (200–600 mg/day). Unfortunately, despite its apparent efficacy as an anxiolytic drug, high dropout rates and the prevalence of adverse side effects associated with fenobam resulted in a discontinuation of clinical trials of this compound. More recently, however, reexaminations of the therapeutic potential of fenobam have been initiated for the treatment of Fragile X syndrome, a common form of mental retardation that involves abnormalities in mGlu5-mediated synaptic plasticity and neuronal development.5–7,105,106 In a recent preliminary report on the safety and tolerability of fenobam in subjects with Fragile X syndrome, fenobam (50–150 mg/day) produced clinical improvements in cognitive function in 9 of 12 patients, including increased eye contact and social interaction, and reduced anxiety and hyperactivity.72 The only side effect observed in 3 of the 12 patients was mild sedation, and no subjects discontinued the trial. Thus, fenobam appeared to be well tolerated in this study. The results of a two clinical trials of the mGlu5 receptor NAM ADX10059 for the treatment of GERD have also recently been published.137 Few details are known about the precise pharmacological properties of ADX10059, yet the mechanistic rationale for the treatment of GERD with mGlu5 NAMs is based on the expression of mGlu5 receptors on brainstem vagal afferents that control the contractility of the lower esophageal sphincter, thereby regulating reflux of stomach acid into the esophagus.138–140 In a small within-subjects placebo-controlled study by Keywood et al.,137 24 subjects with GERD received placebo prior to a high-fat meal on the first day of reflux assessment, followed by ADX10059 at a dose of either 50 or 250 mg/day (n = 12 per group) prior to a high-fat meal on the second day of reflux assessment. ADX10059 significantly reduced acid reflux, and no subjects taking either dose of ADX10059 discontinued the trial. In subjects receiving the 50 mg dose, 1 of 12 subjects reported mild sedation, cough,


287

wires.wiley.com/mts

Advanced Review

and rhinorrhea. In subjects receiving the 250 mg dose, side effects such as dizziness and nausea occurred in 9 of 12 participants, but these side effects resolved following the first or second dose of ADX10059. In a larger randomized double-blind placebocontrolled clinical trial by the same investigators,141 103 GERD patients received either placebo (n = 53) or ADX10059 (n = 50; 120 mg) twice daily for 2 weeks. The results of this study indicated that patients receiving ADX10059 reported a significant reduction in GERD symptoms and reflux, as well as a significantly reduced need to take additional ‘rescue’ antacid medications, as compared to those receiving placebo. Three patients (6%) who received ADX10059 discontinued the trial due to adverse side effects. The most common adverse side effects reported by patients taking ADX10059 were dizziness (16 vs 4% in patients receiving placebo) and vertigo (12 vs 2% in patients receiving placebo), and all adverse side effects were reported to be mild to moderate in severity. Thus, like fenobam, ADX10059 appears to be fairly well tolerated with few adverse side effects that necessitate discontinuation of the medication. The initiation of clinical trials examining the effects of these medications on drug craving, use, and relapse in human drug addicts is eagerly awaited. A Group II mGlu receptor ligand has also recently advanced to clinical trials with promising initial results. In a recent clinical proof-of-concept study by Patil et al.,142 it was reported that LY2140023, a prodrug of the orthosteric mGlu2/3 receptor agonist LY404039, was superior to placebo in alleviating both positive and negative symptoms of schizophrenia and equivalent to effects observed with the atypical antipsychotic olanzapine. Placebo-treated patients demonstrated the highest dropout rate, primarily due to a lack of improvement in symptoms. The onset of symptom alleviation was relatively rapid (i.e., within 1 week). Adverse side effects in patients receiving

LY2140023 were mild to moderate in severity and included insomnia, affect lability, nausea, headache, somnolence, and elevated serum creatine phosphokinase levels. However, dyskinesia, akathisia, and parkinsonian-like symptoms, which are problematic side effects often associated with typical and atypical antipsychotic medications, were not observed in LY2140023-treated patients. These positive findings of the mGlu2/3 receptor agonist prodrug LY2140023 in alleviating the symptoms of schizophrenia without severe side effects are very encouraging. Given the wealth of preclinical data reviewed above showing potential anti-addiction effects of mGlu2/3 receptor agonists and PAMs (the latter of which may produce even fewer side effects and more selectively target mGlu2 or mGlu3 receptors4,143 ), clinical trials on the efficacy of LY2140023 or similar compounds in the treatment of drug addiction need to be initiated.

CONCLUSIONS In summary, the preclinical data published to date provide strong evidence that antagonists or NAMs of Group I (particularly mGlu5) receptors, as well as agonists or PAMs of Group II mGlu receptors, hold the most promise for potential utility as pharmacological aids in the treatment of drug addiction. Given that mGlu5 receptor antagonists and NAMs as well as agonists for mGlu2/3 receptors are currently in clinical trials for various other medical conditions, investigations into the clinical efficacy of these compounds in reducing drug craving, use, and relapse in human drug addicts should be promptly undertaken. However, recent positive preclinical findings with mGlu1 antagonists and mGlu7 agonists should not preclude further investigation into developing ligands for these receptors for potential use as addiction pharmacotherapies.

ACKNOWLEDGMENTS Studies from our laboratory have been supported by Public Health Service grants AA013852 from the National Institute on Alcohol Abuse and Alcoholism and DA024355 and DA025606 from the National Institute on Drug Abuse.

REFERENCES 1. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008, 75:218–265.

288

2. Kalivas PW, Lalumiere RT, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology 2009, 56(suppl):169–173.




3. Uys JD, LaLumiere RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord Drug Targets 2008, 7:482–491. 4. Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009, 30:25–31. 5. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010, 50:295–322. 6. Jaeschke G, Wettstein JG, Nordquist RE, Spooren W. mGlu5 receptor antagonists and their therapeutic potential. Expert Opin Ther Pat 2008, 18: 123–142. 7. Gasparini F, Bilbe G, Gomez-Mancilla B, Spooren W. mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Devel 2008, 11:655–665. 8. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205–237. 9. Hermans E, Challiss RA. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-proteincoupled receptors. Biochem J 2001, 359:465–484. 10. Shigemoto R, Mizuno N. Metabotropic glutamate receptors—immunocytochemical and in situ hybridization analysis. In: Ottersen OP, Storm-Mathisen J, eds. Handbook of Chemical Neuroanatomy: Metabotropic Glutamate Receptors: Immunocytochemical and In Situ Hybridization Analyses. London: Elsevier; 2000, 63–98. 11. Romano C, Sesma MA, McDonald CT, O’Malley K, Van den Pol AN, Olney JW. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 1995, 355:455–469. 12. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 1993, 163:53–57. 13. Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol 1992, 322:121–135. 14. Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem 1992, 267:13361–13368. 15. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, Conquet F. Reinforcing and locomotor stimulant effects of



cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001, 4:873–874. 16. Bird MK, Reid CA, Chen F, Tan HO, Petrou S, Lawrence AJ. Cocaine-mediated synaptic potentiation is absent in VTA neurons from mGlu5-deficient mice. Int J Neuropsychopharmacol 2010, 13:133–141. 17. Novak M, Halbout B, O’Connor EC, Rodriguez Parkitna J, Su T, Chai M, Crombag HS, Bilbao A, Spanagel R, Stephens DN, et al. Incentive learning underlying cocaine-seeking requires mGluR5 receptors located on dopamine D1 receptor-expressing neurons. J Neurosci 2010, 30:11973–11982. 18. Mcgeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 2003, 47:240–242. 19. Yararbas G, Keser A, Kanit L, Pogun S. Nicotineinduced conditioned place preference in rats: sex differences and the role of mGluR5 receptors. Neuropharmacology 2010, 58:374–382. 20. Herzig V, Capuani EM, Kovar KA, Schmidt WJ. Effects of MPEP on expression of food-, MDMAor amphetamine-conditioned place preference in rats. Addict Biol 2005, 10:243–249. 21. Popik P, Wrobel M. Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology 2002, 43:1210–1217. 22. Herzig V, Schmidt WJ. Effects of MPEP on locomotion, sensitization and conditioned reward induced by cocaine or morphine. Neuropharmacology 2004, 47: 973–984. 23. Veeneman MM, Boleij H, Broekhoven MH, Snoeren EM, Guitart MM, Cousijn J, Spooren W, Vanderschuren LJ. Dissociable roles of mGlu5 and dopamine receptors in the rewarding and sensitizing properties of morphine and cocaine. Psychopharmacology 2011, 214:863–876. 24. Lominac KD, Kapasova Z, Hannun RA, Patterson C, Middaugh LD, Szumlinski KK. Behavioral and neurochemical interactions between group I mGluR antagonists and ethanol: potential insight into their antiaddictive properties. Drug Alcohol Depend 2006, 85:142–156. 25. van der Kam EL, De Vry J, Tzschentke TM. 2Methyl-6(phenylethynyl)-pyridine (MPEP) potentiates ketamine and heroin reward as assessed by acquisition, extinction, and reinstatement of conditioned place preference in the rat. Eur J Pharmacol 2009, 606: 94–101. 26. Rutten K, van der Kam EL, De Vry J, Bruckmann W, Tzschentke TM. The mGluR5 antagonist 2-methyl6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats. Addict Biol 2011, 16:108–115.


289

wires.wiley.com/mts

Advanced Review

27. Manzanedo C, Aguilar MA, Minarro J, RodriguezArias M. Effects of CNQX and MPEP on sensitization to the rewarding effects of morphine. Eur J Pharmacol 2011, 654:42–46. 28. van der Kam EL, De Vry J, Tzschentke TM. The mGlu5 receptor antagonist 2-methyl-6(phenyl ethynyl)-pyridine (MPEP) supports intravenous selfadministration and induces conditioned place preference in the rat. Eur J Pharmacol 2009, 607:114–120. 29. Lea PM, Faden AI. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev 2006, 12:149–166. 30. Iso Y, Grajkowska E, Wroblewski JT, Davis J, Goeders NE, Johnson KM, Sanker S, Roth BL, Tueckmantel W, Kozikowski AP. Synthesis and structure-activity relationships of 3-[(2-methyl1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. J Med Chem 2006, 49: 1080–1100. 31. Kenny PJ, Boutrel B, Gasparini F, Koob GF, Markou A. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology 2005, 179:247–254. 32. Kenny PJ, Paterson NE, Boutrel B, Semenova S, Harrison AA, Gasparini F, Koob GF, Skoubis PD, Markou A. Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine selfadministration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci 2003, 1003:415–418. 33. Tessari M, Pilla M, Andreoli M, Hutcheson DM, Heidbreder CA. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 2004, 499: 121–133. 34. Lee B, Platt DM, Rowlett JK, Adewale AS, Spealman RD. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J Pharmacol Exp Ther 2005, 312:1232–1240. 35. Platt DM, Rowlett JK, Spealman RD. Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology 2008, 200:167–176. 36. Martin-Fardon R, Baptista MA, Dayas CV, Weiss F. Dissociation of the effects of MTEP [3-[(2-methyl-1,3thiazol-4-yl)ethynyl]piperidine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer. J Pharmacol Exp Ther 2009, 329:1084–1090.

290

37. Hao Y, Martin-Fardon R, Weiss F. Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence. Biol Psychiatry 2010, 68: 240–248. 38. Paterson NE, Semenova S, Gasparini F, Markou A. The mGluR5 antagonist MPEP decreased nicotine selfadministration in rats and mice. Psychopharmacology 2003, 167:257–264. 39. Tronci V, Vronskaya S, Montgomery N, Mura D, Balfour DJ. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. Psychopharmacology 2010, 211:33–42. 40. Liechti ME, Markou A. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine selfadministration and reward deficits associated with nicotine withdrawal in rats. Eur J Pharmacol 2006, 554:164–174. 41. Palmatier MI, Liu X, Donny EC, Caggiula AR, Sved AF. Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine. Neuropsychopharmacology 2008, 33:2139–2147. 42. van der Kam EL, De Vry J, Tzschentke TM. Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat. Behav Pharmacol 2007, 18:717–724. 43. Gass JT, Osborne MP, Watson NL, Brown JL, Olive MF. mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology 2009, 34:820–833. 44. Backstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 2004, 29:921–928. 45. Olive MF, McGeehan AJ, Kinder JR, McMahon T, Hodge CW, Janak PH, Messing RO. The mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine decreases ethanol consumption via a protein kinase Cε-dependent mechanism. Mol Pharmacol 2005, 67:349–355. 46. McMillen BA, Crawford MS, Kulers CM, Williams HL. Effects of a metabotropic, mglu5, glutamate receptor antagonist on ethanol consumption by genetic drinking rats. Alcohol Alcohol 2005, 40:494–497. 47. Gupta T, Syed YM, Revis AA, Miller SA, Martinez M, Cohn KA, Demeyer MR, Patel KY, Brzezinska WJ, Rhodes JS. Acute effects of acamprosate and MPEP on ethanol drinking-in-the-dark in male C57BL/6J mice. Alcohol Clin Exp Res 2008, 32:1992–1998. 48. Hodge CW, Miles MF, Sharko AC, Stevenson RA, Hillmann JR, Lepoutre V, Besheer J, Schroeder JP. The mGluR5 antagonist MPEP selectively inhibits the




onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology 2006, 183:429–438. 49. Schroeder JP, Overstreet DH, Hodge CW. The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology 2005, 179:262–270. 50. Bird MK, Kirchhoff J, Djouma E, Lawrence AJ. Metabotropic glutamate 5 receptors regulate sensitivity to ethanol in mice. Int J Neuropsychopharmacol 2008, 11:765–774. 51. Cowen MS, Krstew E, Lawrence AJ. Assessing appetitive and consummatory phases of ethanol selfadministration in C57BL/6J mice under operant conditions: regulation by mGlu5 receptor antagonism. Psychopharmacology 2007, 190:21–29. 52. Sidhpura N, Weiss F, Martin-Fardon R. Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of ethanol dependence. Biol Psychiatry 2010, 67:804–811. 53. Blednov YA, Harris RA. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol 2008, 11:775–793. 54. Besheer J, Faccidomo S, Grondin JJ, Hodge CW. Regulation of motivation to self-administer ethanol by mGluR5 in alcohol-preferring (P) rats. Alcohol Clin Exp Res 2008, 32:209–221. 55. Paterson NE, Markou A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology 2005, 179:255–261. 56. Besheer J, Stevenson RA, Hodge CW. mGlu5 receptors are involved in the discriminative stimulus effects of self-administered ethanol in rats. Eur J Pharmacol 2006, 551:71–75. 57. Murray JE, Bevins RA. Behavioral and neuropharmacological characterization of nicotine as a conditional stimulus. Eur J Pharmacol 2007, 561:91–104. 58. O’Connor EC, Crombag HS, Mead AN, Stephens DN. The mGluR5 antagonist MTEP dissociates the acquisition of predictive and incentive motivational properties of reward-paired stimuli in mice. Neuropsychopharmacology 2010, 35:1807–1817. 59. Olsen CM, Childs DS, Stanwood GD, Winder DG. Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5). PLoS One 2010, 5: e15085. 60. Kumaresan V, Yuan M, Yee J, Famous KR, Anderson SM, Schmidt HD, Pierce RC. Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. Behav Brain Res 2009, 202:238–244.



61. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, Kalivas PW. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009, 12:182–189. 62. Schroeder JP, Spanos M, Stevenson JR, Besheer J, Salling M, Hodge CW. Cue-induced reinstatement of alcohol-seeking behavior is associated with increased ERK1/2 phosphorylation in specific limbic brain regions: blockade by the mGluR5 antagonist MPEP. Neuropharmacology 2008, 55:546–554. 63. Bespalov AY, Dravolina OA, Sukhanov I, Zakharova E, Blokhina E, Zvartau E, Danysz W, van Heeke G, Markou A. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cueand schedule-induced reinstatement of nicotine selfadministration behavior in rats. Neuropharmacology 2005, 49(suppl 1):167–178. 64. Backstrom P, Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 2006, 31:778–786. 65. Adams CL, Cowen MS, Short JL, Lawrence AJ. Combined antagonism of glutamate mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats. Int J Neuropsychopharmacol 2008, 11:229–241. 66. Adams CL, Short JL, Lawrence AJ. Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors. Br J Pharmacol 2010, 159:534–542. 67. Gass JT, Olive MF. Role of protein kinase C ε (PKCε) in the reduction of ethanol reinforcement due to mGluR5 antagonism in the nucleus accumbens shell. Psychopharmacology 2009, 204:587–597. 68. Cozzoli DK, Goulding SP, Zhang PW, Xiao B, Hu JH, Ary AW, Obara I, Rahn A, Abou-Ziab H, Tyrrel B, et al. Binge drinking upregulates accumbens mGluR5Homer2-PI3K signaling: functional implications for alcoholism. J Neurosci 2009, 29:8655–8668. 69. Besheer J, Grondin JJ, Cannady R, Sharko AC, Faccidomo S, Hodge CW. Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intake. Biol Psychiatry 2010, 67:812–822. 70. Besheer J, Grondin JJ, Salling MC, Spanos M, Stevenson RA, Hodge CW. Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. J Neurosci 2009, 29:9582–9591. 71. Backstrom P, Hyytia P. Involvement of AMPA/ kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology 2007, 192:571–580. 72. Berry-Kravis EM, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, et al. A pilot open-label single-dose trial


291

wires.wiley.com/mts

Advanced Review

of fenobam in adults with fragile X syndrome. J Med Genet 2009, 46:266–271. 73. Dravolina OA, Danysz W, Bespalov AY. Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats. Psychopharmacology 2006, 187: 397–404. 74. Simonyi A, Schachtman TR, Christoffersen GR. The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 2005, 18: 353–361. 75. Simonyi A, Schachtman TR, Christoffersen GR. Metabotropic glutamate receptor subtype 5 antagonism in learning and memory. Eur J Pharmacol 2010, 639:17–25. 76. Kinney GG, O’Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005, 313:199–206. 77. Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Wantuch C, Popiolek M, Day M, et al. ADX47273: a novel metabotropic glutamate receptor 5 selective positive allosteric modulator with preclinical antipsychotic-like and pro-cognitive activities. J Pharmacol Exp Ther 2008, 327:827–839. 78. Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, More L, Danysz W. Comparison of the mGlu5 receptor positive allosteric modulator ADX47273 and the mGlu2/3 receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol 2009, 623:73–83. 79. Taylor JR, Olausson P, Quinn JJ, Torregrossa MM. Targeting extinction and reconsolidation mechanisms to combat the impact of drug cues on addiction. Neuropharmacology 2009, 56(suppl):186–195. 80. Xu J, Zhu Y, Contractor A, Heinemann SF. mGluR5 has a critical role in inhibitory learning. J Neurosci 2009, 29:3676–3684. 81. Gass JT, Olive MF. Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory. Biol Psychiatry 2009, 65: 717–720. 82. Cleva RM, Hicks MP, Gass JT, Wischerath KC, Plasters ET, Widholm JJ, Olive MF. mGluR5 positive allosteric modulation enhances extinction learning following cocaine self-administration. Behav Neurosci 2011, 125:10–19. 83. Reichel CM, Schwendt M, McGinty JF, Olive MF, See RE. Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 2011, 36:782–792.

292

84. Besheer J, Faccidomo S, Grondin JJ, Hodge CW. Effects of mGlu1-receptor blockade on ethanol selfadministration in inbred alcohol-preferring rats. Alcohol 2008, 42:13–20. 85. Dravolina OA, Zakharova ES, Shekunova EV, Zvartau EE, Danysz W, Bespalov AY. mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology 2007, 52:263–269. 86. Xie X, Ramirez DR, Lasseter HC, Fuchs RA. Effects of mGluR1 antagonism in the dorsal hippocampus on drug context-induced reinstatement of cocaineseeking behavior in rats. Psychopharmacology 2010, 208:1–11. 87. Schoepp DD. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001, 299:12–20. 88. Testa CM, Friberg IK, Weiss SW, Standaert DG. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J Comp Neurol 1998, 390:5–19. 89. Tamaru Y, Nomura S, Mizuno N, Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 2001, 106: 481–503. 90. Ohishi H, Ogawa-Meguro R, Shigemoto R, Kaneko T, Nakanishi S, Mizuno N. Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron 1994, 13:55–66. 91. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 1993, 53: 1009–1018. 92. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 1993, 335: 252–266. 93. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ. LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 1997, 36:1511–1516. 94. Baptista MAS, Martin-Fardon R, Weiss F. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J Neurosci 2004, 24:4723–4727. 95. Peters J, Kalivas PW. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology 2006, 186:143–149.




96. Adewale AS, Platt DM, Spealman RD. Pharmacological stimulation of group II metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys. J Pharmacol Exp Ther 2006, 318: 922–931. 97. Rodd ZA, McKinzie DL, Bell RL, McQueen VK, Murphy JM, Schoepp DD, McBride WJ. The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats. Behav Brain Res 2006, 171:207–215. 98. Backstrom P, Hyytia P. Suppression of alcohol selfadministration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4DCPG. Eur J Pharmacol 2005, 528:110–118. 99. Zhao Y, Dayas CV, Aujla H, Baptista MAS, MartinFardon R, Weiss F. Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci 2006, 26:9967–9974. 100. Lu L, Uejima JL, Gray SM, Bossert JM, Shaham Y. Systemic and central amygdala injections of the mGluR2/3 agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol Psychiatry 2007, 61:591–598. 101. Grimm JW, Hope BT, Wise RA, Shaham Y. Incubation of cocaine craving after withdrawal. Nature 2001, 412:141–142. 102. Lu L, Grimm JW, Hope BT, Shaham Y. Incubation of cocaine craving after withdrawal: a review of preclinical data. Neuropharmacology 2004, 47(suppl 1): 214–226. 103. Jin X, Semenova S, Yang L, Ardecky R, Sheffler DJ, Dahl R, Conn PJ, Cosford ND, Markou A. The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaineseeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology 2010, 35:2021–2036. 104. Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, et al. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem 2011, 54:342–353. 105. Cartmell J, Monn JA, Schoepp DD. Tolerance to the motor impairment, but not to the reversal of PCPinduced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn Schmiedebergs Arch Pharmacol 2000, 361:39–46. 106. Liechti ME, Lhuillier L, Kaupmann K, Markou A. Metabotropic glutamate 2/3 receptors in the ventral



tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 2007, 27:9077–9085. 107. Bossert JM, Liu SY, Lu L, Shaham Y. A role of ventral tegmental area glutamate in contextual cueinduced relapse to heroin seeking. J Neurosci 2004, 24:10726–10730. 108. Bossert JM, Gray SM, Lu L, Shaham Y. Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology 2006, 31:2197–2209. 109. Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R, Mizuno N, Nakanishi S. Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphono butyrate. J Biol Chem 1993, 268:11868–11873. 110. Corti C, Aldegheri L, Somogyi P, Ferraguti F. Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience 2002, 110:403–420. 111. Kinzie JM, Saugstad JA, Westbrook GL, Segerson TP. Distribution of metabotropic glutamate receptor 7 messenger RNA in the developing and adult rat brain. Neuroscience 1995, 69:167–176. 112. Saugstad JA, Kinzie JM, Shinohara MM, Segerson TP, Westbrook GL. Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct pharmacological profile. Mol Pharmacol 1997, 51: 119–125. 113. Blednov YA, Walker D, Osterndorf-Kahanek E, Harris RA. Mice lacking metabotropic glutamate receptor 4 do not show the motor stimulatory effect of ethanol. Alcohol 2004, 34:251–259. 114. Li X, Li J, Peng XQ, Spiller K, Gardner EL, Xi ZX. Metabotropic glutamate receptor 7 modulates the rewarding effects of cocaine in rats: involvement of a ventral pallidal GABAergic mechanism. Neuropsychopharmacology 2009, 34:1783–1796. 115. Li X, Li J, Gardner EL, Xi ZX. Activation of mGluR7s inhibits cocaine-induced reinstatement of drugseeking behavior by a nucleus accumbens glutamatemGluR2/3 mechanism in rats. J Neurochem 2010, 114:1368–1380. 116. Salling MC, Faccidomo S, Hodge CW. Nonselective suppression of operant ethanol and sucrose selfadministration by the mGluR7 positive allosteric modulator AMN082. Pharmacol Biochem Behav 2008, 91: 14–20. 117. Vadasz C, Saito M, Gyetvai BM, Oros M, Szakall I, Kovacs KM, Prasad VV, Toth R. Glutamate receptor metabotropic 7 is cis-regulated in the mouse brain and modulates alcohol drinking. Genomics 2007, 90:690–702.


293

wires.wiley.com/mts

Advanced Review

118. Parelkar NK, Wang JQ. Upregulation of metabotropic glutamate receptor 8 mRNA expression in the rat forebrain after repeated amphetamine administration. Neurosci Lett 2008, 433:250–254.

130. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009, 8:41–54.

119. Mao L, Wang JQ. Differentially altered mGluR1 and mGluR5 mRNA expression in rat caudate nucleus and nucleus accumbens in the development and expression of behavioral sensitization to repeated amphetamine administration. Synapse 2001, 41:230–240.

131. Itil TM, Seaman PA, Huque M, Mukhopadhyay S, Blasucci D, Tat K, Ciccone PE. The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr Ther Res 1978, 24:708–724.

120. Ghasemzadeh MB, Nelson LC, Lu XY, Kalivas PW. Neuroadaptations in ionotropic and metabotropic glutamate receptor mRNA produced by cocaine treatment. J Neurochem 1999, 72:157–165. 121. Swanson CJ, Baker DA, Carson D, Worley PF, Kalivas PW. Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: a potential role for Homer. J Neurosci 2001, 21:9043–9052. 122. Xi ZX, Ramamoorthy S, Baker DA, Shen H, Devadoss J, Kalivas PW. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther 2002, 308:608–615. 123. Simonyi A, Christian MR, Sun AY, Sun GY. Chronic ethanol-induced subtype- and subregion-specific decrease in the mRNA expression of metabotropic glutamate receptors in rat hippocampus. Alcohol Clin Exp Res 2004, 28:1419–1423. 124. Obara I, Bell RL, Goulding SP, Reyes CM, Larson LA, Ary AW, Truitt WA, Szumlinski KK. Differential effects of chronic ethanol consumption and withdrawal on homer/glutamate receptor expression in subregions of the accumbens and amygdala of P rats. Alcohol Clin Exp Res 2009, 33: 1924–1934. 125. Ghasemzadeh MB, Mueller C, Vasudevan P. Behavioral sensitization to cocaine is associated with increased glutamate receptor trafficking to the postsynaptic density after extended withdrawal period. Neuroscience 2009, 159:414–426.

132. Pecknold JC, McClure DJ, Appeltauer L. Fenobam in anxious outpatients. Curr Ther Res 1980, 27: 119–123. 133. Friedmann CTH, Davis LJ, Ciccone PE, Rubin RT. Phase II double-blind controlled study of a new anxiolytic, fenobam (McN-3377) vs. placebo. Curr Ther Res 1980, 27:144–151. 134. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982, 2:129–133. 135. Porter RH, Jaeschke G, Spooren W, Ballard T, Buettelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, et al. Fenobam: a clinically validated non-benzodiazepine anxiolytic is a potent, selective and non-competitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005, 315:711–721. 136. Montana MC, Cavallone LF, Stubbert KK, Stefanescu AD, Kharasch ED, Gereau RW. The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity as compared to the prototypical antagonist 2-methyl6-(phenylethynyl)-pyridine. J Pharmacol Exp Ther 2009, 330:834–843. 137. Keywood C, Wakefield M, Tack J. A proof of concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastroesophageal reflux disease. Gut 2009, 58:1192–1199.

126. Mitrano DA, Arnold C, Smith Y. Subcellular and subsynaptic localization of group I metabotropic glutamate receptors in the nucleus accumbens of cocainetreated rats. Neuroscience 2008, 154:653–666.

138. Boeckxstaens GE. Emerging drugs for gastroesophageal reflux disease. Expert Opin Emerg Drugs 2009, 14:481–491.

127. Luscher C, Huber KM. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 2010, 65:445–459.

139. Johnson DA, Levy BH III. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors. Expert Opin Pharmacother 2010, 11:1541–1548.

128. Luscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 2011, 69:650–663.

140. Blondeau K. Treatment of gastro-esophageal reflux disease: the new kids to block. Neurogastroenterol Motil 2010, 22:836–840.

129. Lindsley CW, Emmitte KA. Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 2009, 12:446–457.

141. Zerbib F, Bruley des Varannes S, Roman S, Tutuian R, Galmiche JP, Mion F, Tack J, Malfertheiner P, Keywood C. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor,

294





on symptoms and reflux events in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 2011, 33:911–921.

a randomized phase 2 clinical trial. Nat Med 2007, 13: 1102–1107.

142. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia:

143. Fraley ME. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat 2009, 19:1259–1275.

FURTHER READING Herman BH, ed. Glutamate and Addiction. In: Lydic R, Baghdoyan HA, series eds. Contemporary Clinical Neuroscience. Totowa, NJ: Humana Press; 2002. Koob GF, LeMoal M. Neurobiology of Addiction. San Diego, CA: Academic Press; 2006. Koob GF, Shippenberg TS. Recent advances in animal models of drug addiction. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology—5th Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002, 1381–1397. Olmstead MC. Animal models of drug addiction: where do we go from here? Q J Exp Psychol (Colchester) 2006, 59:625–653.



295